Inclusion Criteria:

        Patients must meet all the following criteria to be eligible for participation in the
        study:

          -  Male or female patients, ≥18 years.

          -  Patients with documented (histologically or cytologically proven) unresectable,
             locally advanced, or metastatic malignancies:

               1. Urothelial cancer (UC)

               2. Small cell lung cancer (SCLC)

               3. Endometrial cancer (EC) of any histological subtype

               4. Cholangiocarcinoma (CCA): unresectable or metastatic adenocarcinoma of the intra-
                  and/or extra-hepatic bile ducts

          -  Patients with UC, SCLC, and EC must have received prior anti-PD-(L)1 therapy with a
             best response of CR/PR or durable SD

          -  Patients with measurable disease according to RECIST v1.1

          -  Patients with an ECOG PS of 0 or 1, and anticipated life expectancy of ≥3 months

          -  Patients must have adequate organ function as indicated by laboratory values

          -  Adequate contraception required as appropriate

        Exclusion Criteria:

          -  Has central nervous system (CNS) malignancies

          -  Patients with significant cardiovascular disease

          -  Patients with

               1. Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism,
                  within 4 weeks prior to the first study drug dose

               2. Active uncontrolled bleeding or a known bleeding diathesis

          -  Patients with a significant pulmonary disease or condition

          -  Patients with a current or recent (within 6 months) significant gastrointestinal
             disease or condition

          -  Patients with a significant ocular disease or condition

          -  Patients with an active, known or suspected autoimmune disease

          -  Patients with any other serious/active/uncontrolled infection

          -  Prior therapy with anti-LAG-3 or anti-TIM-3 or combinations of these 2 antibodies with
             anti-PD-(L)1 antibody or with any other systemic or localized therapy

          -  Patients with a history of significant toxicities associated with previous
             administration of immune checkpoint inhibitors that necessitated permanent
             discontinuation of that therapy

          -  Patients with a known or suspected hypersensitivity to any of the excipients of
             formulated study drug

          -  Patients with unresolved >Grade 1 toxicity associated with any prior antineoplastic
             therapy